ENVOCANA

Serial Number 85652132
606

Registration Progress

Application Filed
Jun 14, 2012
Under Examination
Oct 16, 2012
Approved for Publication
Aug 21, 2012
Published for Opposition
Aug 21, 2012
Registered

Trademark Image

ENVOCANA

Basic Information

Serial Number
85652132
Filing Date
June 14, 2012
Published for Opposition
August 21, 2012
Abandonment Date
November 18, 2013
Drawing Code
4000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Nov 18, 2013
Classes
005

Rights Holder

JOHNSON & JOHNSON

03
Address
One Johnson & Johnson Plaza
New Brunswick, NJ 089337001

Ownership History

JOHNSON & JOHNSON

Original Applicant
03
New Brunswick, NJ

JOHNSON & JOHNSON

Owner at Publication
03
New Brunswick, NJ

Legal Representation

Attorney
Laurence S. Rickles

USPTO Deadlines

All Deadlines Cleared

All 2 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

14 events
Date Code Type Description Documents
Nov 18, 2013 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Nov 18, 2013 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
Apr 2, 2013 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Mar 29, 2013 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Mar 29, 2013 EXT1 S SOU EXTENSION 1 FILED Loading...
Mar 29, 2013 EX1G S SOU EXTENSION 1 GRANTED Loading...
Oct 16, 2012 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Aug 21, 2012 PUBO A PUBLISHED FOR OPPOSITION Loading...
Aug 21, 2012 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Aug 1, 2012 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Jul 16, 2012 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Jul 10, 2012 DOCK D ASSIGNED TO EXAMINER Loading...
Jun 22, 2012 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jun 18, 2012 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Human pharmaceuticals for the treatment of infectious-related disease, auto-immune and inflammatory diseases, cardiovascular diseases, central nervous system diseases and pain, dermatologic disorders, metabolic diseases, anti-viral diseases, oncologic diseases, respiratory diseases, ophthalmic diseases and gastro-intestinal diseases
First Use Anywhere: 0
First Use in Commerce: 0

Classification

International Classes
005